Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service SI joint fusion cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 16% on average (37 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 0 | 115 | 46% |
| 2020 | 1 | 127 | 48% |
| 2021 | 1 | 113 | 51% |
| 2022 | 2 | 137 | 53% |
| 2023 | 1 | 143 | 55% |
| 2024 | 0 | 175 | 57% |
| 2025 from claims | – | 292 236–342 | 58% |
| 2026 forecast | – | 319 250–401 | 58% |
| 2027 forecast | – | 348 258–460 | 59% |
| 2028 forecast | – | 379 268–523 | 59% |
| 2029 forecast | – | 413 280–592 | 60% |
| 2030 forecast | – | 449 294–667 | 60% |
Minimally invasive and open sacroiliac joint fusion. Professional codes (what the surgeon bills): CPT 27279, 27280, 0775T, 27278.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
No metro breakdown yet.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 3 | 212+10%/yr | +10%/yr | 0.1 | 16% | 590 in 2030+19%/yr |
| New Jersey | 3 | 157+9.2%/yr | +9.2%/yr | 0.1 | 100% | 260 in 2030+9.1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 113 | 4,671−4.3%/yr | −4.3%/yr | 2.50.9× | 3% | 4,720 in 2030+0.2%/yr |
| Lumbar fusion | 96 | 3,407−0.3%/yr | −0.3%/yr | 1.80.8× | 1% | 4,050 in 2030+2.9%/yr |
| Cervical fusion & disc arthroplasty | 35 | 1,875−1.6%/yr | −1.6%/yr | 1.00.9× | 2% | 1,980 in 2030+0.9%/yr |
| Kyphoplasty & vertebroplasty | 12 | 1,432−3.1%/yr | −3.1%/yr | 0.80.9× | 29% | 1,740 in 2030+3.3%/yr |
SI joint fusion in every state, and its device makers · Every procedure market in New York · Every state · Compare with Pennsylvania
SI-BONE leads with 96% of company spending on these surgeons in 2025, +18 pts on 2024.
In 2025, 4 companies reported engagement with New York’s surgeons worth $90K in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 7 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.